JP7463306B2 - 関節内ステロイドの合併症を軽減する方法 - Google Patents

関節内ステロイドの合併症を軽減する方法 Download PDF

Info

Publication number
JP7463306B2
JP7463306B2 JP2020573183A JP2020573183A JP7463306B2 JP 7463306 B2 JP7463306 B2 JP 7463306B2 JP 2020573183 A JP2020573183 A JP 2020573183A JP 2020573183 A JP2020573183 A JP 2020573183A JP 7463306 B2 JP7463306 B2 JP 7463306B2
Authority
JP
Japan
Prior art keywords
weeks
pharmaceutical composition
steroid
steroids
joint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532074A (ja
JP2021532074A5 (https=
Inventor
シェウ－ファン シー
ポ－チュン チャン
ミン－ジュ ウー
Original Assignee
タイワン リポソーム カンパニー リミテッド
ティーエルシー バイオファーマシューティカルズ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タイワン リポソーム カンパニー リミテッド, ティーエルシー バイオファーマシューティカルズ、インク． filed Critical タイワン リポソーム カンパニー リミテッド
Publication of JP2021532074A publication Critical patent/JP2021532074A/ja
Publication of JP2021532074A5 publication Critical patent/JP2021532074A5/ja
Application granted granted Critical
Publication of JP7463306B2 publication Critical patent/JP7463306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020573183A 2018-07-09 2019-07-08 関節内ステロイドの合併症を軽減する方法 Active JP7463306B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862695763P 2018-07-09 2018-07-09
US62/695,763 2018-07-09
US201962839231P 2019-04-26 2019-04-26
US62/839,231 2019-04-26
PCT/US2019/040794 WO2020014118A1 (en) 2018-07-09 2019-07-08 Methods to reduce complications of intra-articular steroid

Publications (3)

Publication Number Publication Date
JP2021532074A JP2021532074A (ja) 2021-11-25
JP2021532074A5 JP2021532074A5 (https=) 2023-08-29
JP7463306B2 true JP7463306B2 (ja) 2024-04-08

Family

ID=67441711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573183A Active JP7463306B2 (ja) 2018-07-09 2019-07-08 関節内ステロイドの合併症を軽減する方法

Country Status (12)

Country Link
US (1) US12083138B2 (https=)
EP (1) EP3820479B1 (https=)
JP (1) JP7463306B2 (https=)
KR (2) KR20210031715A (https=)
CN (1) CN112469420A (https=)
AU (1) AU2019301542B2 (https=)
BR (1) BR112021000316A2 (https=)
CA (1) CA3105743A1 (https=)
SG (1) SG11202100054YA (https=)
TW (1) TWI857961B (https=)
WO (1) WO2020014118A1 (https=)
ZA (1) ZA202100604B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023019192A1 (en) * 2021-08-11 2023-02-16 Board Of Regents, The University Of Texas System Dry liposome formulations and related methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130296267A1 (en) 2008-01-18 2013-11-07 Horst Kief Agent for intra-articular injection
JP2015522041A (ja) 2012-07-05 2015-08-03 タイワン リポソーム カンパニー リミテッド 関節炎の処置方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE10255106A1 (de) * 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
US8956600B2 (en) 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
RU2660585C2 (ru) * 2012-02-10 2018-07-06 Тайвэн Липосом Компани, Лтд. Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний
TWI845973B (zh) 2015-01-21 2024-06-21 美商桑紐爾製藥公司 醫藥配方

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130296267A1 (en) 2008-01-18 2013-11-07 Horst Kief Agent for intra-articular injection
JP2015522041A (ja) 2012-07-05 2015-08-03 タイワン リポソーム カンパニー リミテッド 関節炎の処置方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Clinical and Experimental Rheumatology，2002年，Vol.20，p.773-781
Ｅｌｒｏｎ－Ｇｒｏｓｓ Ｉ． ｅｔ ａｌ．， Ｌｉｐｏｓｏｍａｌ ｄｅｘａｍｅｔｈａｓｏｎｅ－ｄｉｃｌｏｆｅｎａｃ ｃｏｍｂｉｎａｔｉｏｎ ｆｏｒ ｌｏｃａｌ ｏｓｔｅｏａｒｔｈｒｉｔｉｓ ｔｒｅａｔｍｅｎｔ，Int. J. Pharmaceutics，Vol.376，2009年，p.84-91
Ｈｅｌｌｍｉｃｈ Ｄ． ｅｔ ａｌ．， Ａｃｕｔｅ Ｔｒｅａｔｍｅｎｔ ｏｆ Ｆａｃｅｔ Ｓｙｎｄｒｏｍｅ ｂｙ ＣＴ－Ｇｕｉｄｅｄ Ｉｎｊｅｃｔｉｏｎ ｏｆ Ｄｅｘａｍｅｔｈａｓｏｎｅ－２１－Ｐａｌｍｉｔａｔｅ Ａｌｏｎｅ ａｎｄ ｉｎ Ｃｏｍｂｉｎａｔｉｏｎ ｗｉｔｈ Ｍｅｐｉｖａｃａｉｎｅ，Clin. Drug Invest.，Vol.24，2004年，p.559-567
Molecular Pharmaceutics，2011年，Vol.8，p.1002-1015
Ｒａｕｃｈｈａｕｓ Ｕ ｅｔ ａｌ． ，Ｓｅｐａｒａｔｉｎｇ ｔｈｅｒａｐｅｕｔｉｃ ｅｆｆｉｃａｃｙ ｆｒｏｍ ｇｌｕｃｏｃｏｒｔｉｃｏｉｄ ｓｉｄｅ－ｅｆｆｅｃｔｓ ｉｎ ｒｏｄｅｎｔ ａｒｔｈｒｉｔｉｓ ｕｓｉｎｇ ｎｏｖｅｌ， ｌｉｐｏｓｏｍａｌ ｄｅｌｉｖｅｒｙ ｏｆ ｄｅｘａｍｅｔｈａｓｏｎｅ ｐｈｏｓｐｈａｔｅ： ｌｏｎｇ－ｔｅｒｍ ｓｕｐｐｒｅｓｓｉｏｎ ｏｆ ａｒｔｈｒｉｔｉｓ ｆａｃｉｌｉｔａｔｅｓ ｉｎｔｅｒｖａｌ ｔｒｅａｔｍｅｎｔ，Arthritis Res. & Thera.，Vol.11，2009年，R190
油化学，1985年，Vol.34, No.10，p.784-798

Also Published As

Publication number Publication date
EP3820479B1 (en) 2026-03-11
AU2019301542A1 (en) 2021-02-25
JP2021532074A (ja) 2021-11-25
TWI857961B (zh) 2024-10-11
AU2019301542B2 (en) 2025-04-03
TW202007398A (zh) 2020-02-16
CA3105743A1 (en) 2020-01-16
EP3820479A1 (en) 2021-05-19
US12083138B2 (en) 2024-09-10
SG11202100054YA (en) 2021-02-25
ZA202100604B (en) 2025-05-28
CN112469420A (zh) 2021-03-09
BR112021000316A2 (pt) 2021-04-06
KR20210031715A (ko) 2021-03-22
WO2020014118A1 (en) 2020-01-16
KR20250093579A (ko) 2025-06-24
US20210196733A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
US10350294B2 (en) Pharmaceutical compositions to reduce complications of ocular steroid
JP7634476B2 (ja) 関節への送達に適した医薬組成物及びその関節痛の治療における使用
ES3058285T3 (en) Pharmaceutical compositions with reduced side effect and methods of using the same
JP7463306B2 (ja) 関節内ステロイドの合併症を軽減する方法
RU2806023C2 (ru) Способы уменьшения осложнений от внутрисуставного стероида
HK40041258A (en) Methods to reduce complications of intra-articular steroid
US12514820B2 (en) Pharmaceutical composition of intra-articular corticosteroid for pain control
RU2810788C2 (ru) Фармацевтические композиции, подходящие для суставной доставки, и их применение при лечении суставной боли
HK40041739A (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
HK40087158A (zh) 用於疼痛控制的关节内皮质类固醇的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220606

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240327

R150 Certificate of patent or registration of utility model

Ref document number: 7463306

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150